A randomized, multicenter, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of intrathecal administration of RO7234292 (RG6042) in patients with manifest Huntington's disease
Phase 5 study testing RG6042 in Huntington's disease.
Active, not recruiting5DrugJPRNTreatment trial
Recruiting in: Japan
Preparing a short plain-English summary.